Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...
Alto Neuroscience missed the primary endpoint for a study of its ALTO-101 drug for the treatment of cognitive impairment associated with schizophrenia.
Forbes contributors publish independent expert analyses and insights. Steven covers accessibility and assistive technologies. I’ve taken Lyft and Uber rides all over San Francisco in 9 years here.
Investor worries grow over AI's threat to stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results